Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo

• DOI: 10.1016/j.intimp.2007.09.012
• Publication Date: 2007-10-05T11:12:24Z
• Authors: Linghua Zhang; Xingshan Tian; Fengzhen Zhou
• Keywords: Interleukin-6; Swine; Viral Vaccines; Antibodies, Viral; 3. Good health; Interferon-gamma; 03 medical and health sciences; 0302 clinical medicine; Adjuvants, Immunologic; Oligodeoxyribonucleotides; Vaccines, Inactivated; Animals; Porcine respiratory and reproductive syndrome virus; Immunity, Mucosal; Administration, Intranasal

Oligonucleotides containing CpG motifs (CpG ODN) are strong adjuvants for immune responses, particularly in mice. Recently, it has been showed that CpG ODN is a promising mucosal adjuvant in mice, but data on mucosal immune responses induced by CpG ODN in piglets are scarce. We have previously demonstrated that CpG ODN is a potent adjuvant to pseudorabies attenuated virus (PRV) vaccine when administered subcutaneously (SC) in newborn piglets. Herein, we evaluated intranasal (IN) delivery of CpG ODN with porcine reproductive and respiratory syndrome (PRRS) killed virus vaccine (PRRSV) to determine its potential as a mucosal adjuvant to a commercial vaccine. CpG ODN augmented systemic (IgG in serum, Peripheral blood mononuclear cells (PBMC) proliferation) and mucosal (IgA in feces, nasal and oral secretions) immune responses against antigen. CpG ODN stimulated both T-helper type1 (Type 1) (IgG2) and Type 2 (IgA) responses when delivered intranasally. Results from this study indicate that stimulatory CpG ODN may be effective as a mucosal adjuvant with commercial vaccine in husbandry animals.